Indraprastha Medical Corporation Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
INDRAMEDCO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Indraprastha Medical Corporation (Indraprastha Apollo Hospitals) reported Q2 FY26 revenue from operations of Rs. 381.03 crore, up about 8.9% from Rs. 349.82 crore in Q2 FY25. Profit after tax grew to Rs. 49.46 crore from Rs. 42.40 crore, a rise of roughly 16.7% year-on-year, taking H1 FY26 PAT to Rs. 100.92 crore (vs Rs. 87.17 crore in H1 FY25). EPS for Q2 stood at Rs. 5.40 compared to Rs. 4.63 a year earlier. Total income for the half-year was Rs. 760.36 crore, and profit before tax was Rs. 134.62 crore. The auditor (SN Dhawan & CO LLP) issued a clean limited review report with no qualifications, and there were no exceptional items in the quarter. The company operates only in healthcare and has no subsidiaries.
Steady mid-teens earnings growth and a slight improvement in operating margins signal stable business momentum, likely to be viewed positively by shareholders, though the absence of any sharp acceleration may limit upside surprises in the stock price.